Generation Bio Co (Generation Bio Co) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Generation Bio Co Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Generation Bio Co's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. The number is 0, which means that Generation Bio Co has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Generation Bio Co's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Generation Bio Co Net Issuance of Preferred Stock Historical Data

The historical data trend for Generation Bio Co's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Net Issuance of Preferred Stock Chart

Generation Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

108.85

Generation Bio Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Generation Bio Co Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Generation Bio Co Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Generation Bio Co (Generation Bio Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.generationbio.com

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.

Executives

Dannielle Appelhans	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson	director	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Antoinette Paone	officer: CHIEF OPERATING OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Yalonda Howze	officer: CHIEF LEGAL OFFICER	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa	officer: CHIEF STRATEGY OFFICER	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p.	10 percent owner	400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton	officer: Chief Scientific Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough	director, 10 percent owner, officer: See Remarks	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann	officer: Chief Development Officer	C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino	officer: Chief Operating Officer	GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142